Mevidalen Study for Alzheimer's Disease

This study looks at how safe and effective the drug mevidalen is for people with Alzheimer's Disease, which affects memory and thinking. The study will last about 26 weeks, which is about 6 months, and it involves up to 14 visits to the study center. The study checks changes in thinking, daily activities, sleep, and any feelings of irritability or anxiety.

• **Duration:** The study lasts around 6 months.
• **Visits:** Participants may need to visit the study site up to 14 times.
• **Requirements:** Participants need a reliable partner and cannot have certain health conditions.

Eligibility: Participants should have memory loss affecting daily life for at least 6 months, a Mini-Mental State Examination (MMSE) score between 13 and 24, and certain markers of Alzheimer's in their blood. Participants need a partner who can provide consent and be available for study visits. Men must agree to follow birth control guidance.

Exclusions: People who can have children, have other brain or psychiatric diseases, or certain heart or liver problems cannot participate. Also, those who have recently taken part in another drug study or are at risk of self-harm are not eligible. Certain medications cannot be taken during the study.